Get the Stockscreener App
319.86
7.81%
23.16
After Hours:
319.93
0.07
+0.02%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $319.86, with a volume of 5.48M.
It is up +7.81% in the last 24 hours and up +7.38% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$296.70
Open:
$303.125
24h Volume:
5.48M
Relative Volume:
2.34
Market Cap:
$172.20B
Revenue:
$34.76B
Net Income/Loss:
$6.62B
P/E Ratio:
26.17
EPS:
12.223
Net Cash Flow:
$10.61B
1W Performance:
+9.63%
1M Performance:
+7.38%
6M Performance:
+14.21%
1Y Performance:
+0.18%
1-Day Range:
$302.13
$322.98
1-Week Range:
$288.00
$322.98
52-Week Range:
$253.30
$335.88
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
319.86 | 159.73B | 34.76B | 6.62B | 10.61B | 12.22 |
|
LLY
Lilly Eli Co
|
925.81 | 811.66B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.00 | 450.20B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
216.77 | 381.38B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.50 | 239.87B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
84.39 | 209.46B | 63.99B | 19.05B | 14.72B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (NASDAQ:AMGN) Updates FY 2025 Earnings Guidance - MarketBeat
Amgen (NASDAQ:AMGN) Posts Quarterly Earnings Results, Beats Expectations By $0.63 EPS - MarketBeat
Biotech Shines As Amgen And Teva Surprise, Humana Sinks - Finimize
Key facts: Amgen raises 2025 revenue outlook; VESALIUS-CV trial success; Wells Fargo boosts price target - TradingView
Why Amgen Stock Was Crushing It on Wednesday - Yahoo Finance
Morgan Stanley Adjusts Price Target for Amgen (AMGN) | AMGN Stoc - GuruFocus
Amgen Warns Against Turning Biosimilars Into Generics - Citeline News & Insights
Amgen, Caterpillar share gains contribute to Dow's 250-point jump - MSN
Amgen: Q3 Earnings Indicate Strong Emphasis On R&D (NASDAQ:AMGN) - Seeking Alpha
Amgen Surges After Lifting Forecast--New Drugs and Obesity Bet Ignite Investor Hopes - Yahoo Finance
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up - TradingView
Amgen's New Launches, Pipeline Progress in Focus After Q3 Earnings Beat, Morgan Stanley Says - MarketScreener
Amgen price target lowered to $329 from $333 at Morgan Stanley - TipRanks
Amgen (AMGN): Wells Fargo Raises Price Target to $300 | AMGN Sto - GuruFocus
Amgen lifts outlook after strong third-quarter performance - The Pharma Letter
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Amgen, Cloudflare, Shopify, Super Micro Computer, Wingstop and More - MSN
Amgen profit beats estimates, weight-loss data due by year-end - Reuters
Morgan Stanley Adjusts Price Target on Amgen to $329 From $333, Maintains Equalweight Rating - MarketScreener
AMGN Q3 Deep Dive: Broad-Based Product Momentum and Pipeline Progress Drive Upbeat Guidance - TradingView
Here Are Wednesday's Top Wall Street Analyst Research Calls: Amgen, Cloudflare, Shopify, Super Micro Computer, Wingstop and More - 24/7 Wall St.
GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report - Yahoo Finance
NewSquare Capital LLC Has $7.28 Million Position in Amgen Inc. $AMGN - MarketBeat
Baird reiterates Underperform rating on Amgen stock, maintains $215 price target - Investing.com Nigeria
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 174,976 Shares of Amgen Inc. $AMGN - MarketBeat
Morgan Stanley Trims Price Target on Amgen to $329 From $333, Keeps Equalweight Rating - MarketScreener
Commonwealth Retirement Investments LLC Raises Holdings in Amgen Inc. $AMGN - MarketBeat
AMGEN INC SEC 10-Q Report - TradingView
Huntington National Bank Decreases Holdings in Amgen Inc. $AMGN - MarketBeat
What dividend safety score for Amgen Inc. stockJobs Report & Fast Entry Momentum Trade Alerts - newser.com
Amgen beats third-quarter forecasts aided by one-offs, shares up - Investing.com Nigeria
Is Amgen’s Pipeline Progress Signaling More Upside After a 14.4% Year-to-Date Gain? - simplywall.st
Will breakout in Amgen Inc. lead to full recoveryQuarterly Earnings Report & High Accuracy Trade Alerts - newser.com
Amgen nudges up annual targets - MarketScreener
Institutional scanner results for Amgen Inc.2025 Key Lessons & Fast Exit and Entry Trade Guides - newser.com
Amgen Inc (AMGN) Q3 2025 Earnings Call Highlights: Strong Revenu - GuruFocus
Why Amgen Inc. (AMG) stock could be top winnerMarket Activity Report & High Accuracy Buy Signal Tips - newser.com
Amgen Inc. Reports Strong Q3 2025 Financial Results - TipRanks
Amgen’s Phase 3 Study on Rocatinlimab: A Potential Game-Changer for Prurigo Nodularis - MSN
Amgen’s Revenue Grows As It Awaits Phase III Data For Next Potential Blockbuster - Citeline News & Insights
Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study - MarketScreener
Amgen (AMGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo! Finance Singapore
Amgen (AMGN) Surpasses Q3 Expectations with Strong Drug Sales - GuruFocus
Amgen (AMGN) Reports Strong Q3 2025 Earnings with 12% Revenue Gr - GuruFocus
Why global investors buy Amgen Inc. (AMG0) stockEarnings Overview Report & AI Powered Trade Plan Recommendations - newser.com
Amgen Q3 2025 slides: Revenue up 12%, guidance raised on strong product performance - Investing.com
Earnings call transcript: Amgen Q3 2025 results exceed expectations, stock rises - Investing.com
Atherosclerotic Cardiovascular Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Amgen Inc., Merck Sharp & Dohme Corp., NewAmsterdam Pharma - Barchart.com
Amgen Lifts Outlook Again After Drug Sales Beat Expectations (AMGN) - Bloomberg.com
Amgen (AMGN) Surpasses Q3 Earnings and Revenue Expectations - GuruFocus
As Repatha sales surge, Amgen teases 'landmark' results due at AHA - FirstWord Pharma
Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates - Nasdaq
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):